On April 21, 2026, the FDA approved Merck's IDVYNSO (doravirine 100 mg / islatravir 0.25 mg) as a complete once-daily, two-drug oral regimen for HIV-1 — the first non-INSTI, tenofovir-free single-tablet treatment to clear regulators. The approval is a switch indication: it's authorized for adults already virologically suppressed on a stable regimen with no history of treatment failure or known resistance to either drug, allowing them to consolidate to one pill without changing efficacy.

Why It Matters

HIV treatment, prevention (PrEP), and at-home STI testing sit at the intersection of sexual wellness and clinical medicine, and the antiretroviral market is one of the largest in pharma. A successful tenofovir-free Merck launch reshapes Gilead's monopoly on the long-term-suppressed population — typically gay and bisexual men, sex workers, and serodiscordant couples who are the core users of telehealth platforms like Mistr (HIV-focused) and the broader sexual health telehealth ecosystem. Long-term, an islatravir-based long-acting PrEP would be transformative for prevention coverage in populations underserved by daily Truvada/Descovy regimens.

In Phase 3 head-to-head trials, IDVYNSO showed non-inferior efficacy vs. Gilead's blockbuster Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) at 48 weeks of viral suppression. The tenofovir-free profile is the differentiator — tenofovir-based regimens have well-documented bone density and renal impacts that accumulate over decades of treatment, particularly relevant for the long-term suppressed population that now represents the bulk of HIV patients. IDVYNSO also offers a smaller pill size and removes the need for renal monitoring associated with TDF/TAF formulations.

Commercial availability began at U.S. pharmacies after May 11, 2026, per Merck's launch timeline. The approval represents a significant Merck push into the HIV antiretroviral market, where Gilead has dominated with Biktarvy ($12B+ in 2024 global sales). Doravirine (sold as Pifeltro) and islatravir (Merck's nucleoside reverse transcriptase translocation inhibitor, or NRTTI) had previously been studied separately and as part of larger combinations; IDVYNSO is the first single-tablet co-formulation.

The clinical implications extend beyond HIV treatment. Islatravir was originally being developed as a once-monthly oral PrEP candidate before lymphocyte concerns paused that program in 2021; the lower 0.25 mg dose in IDVYNSO addressed those concerns and reopened the door to potentially longer-acting formulations. Merck has signaled that an islatravir-based long-acting PrEP could follow if IDVYNSO uptake validates the lower-dose safety profile.

Sources

Update — 2026-04-26

Initial entry — story first created.